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Purpose or Objective: To investigate the impact of tumour 
volume, hypoxia and cancer stem cell (CSC) marker 
expression on outcome of patients with locally advanced 
head and neck squamous cell carcinoma (HNSCC) after 
primary radiochemotherapy.  
 
Material and Methods: In this retrospective multicentre 
study, 160 patients with squamous cell carcinoma of the oral 
cavity, oropharynx and hypopharynx were included. All 
patients received primary cisplatin-based radiochemotherapy 
(RCT) between 2005 and 2011. Their median follow-up was 
about 26 months. Primary and nodal gross tumour volume 
(GTV) segmentations were performed centrally in the 
computer tomography-based radiation treatment plans. HPV 
status (p16 overexpression) and CD44 expression were 
analysed by immunohistochemistry. Gene expression analysis 
was performed for hypoxia-associated genes and the 
potential CSC marker SLC3A2. Results of the biomarker 
analyses, clinical parameters and tumour volume were 
correlated with the clinical outcome. Primary endpoint was 
loco-regional control (LRC). Secondary endpoints were 
distant metastases (DM) and overall survival (OS).  
 
Results: In univariate analysis, tumour volume, HPV status 
and CSC marker expression were significantly associated with 
LRC (tumour volume: HR 1.51, p=0.02; HPV: HR 0.30, p=0.02; 
CD44: HR 2.30, p=0.04; SLC3A2: HR 2.08, p=0.01). 
Interestingly, hypoxia showed a significant association with 
LRC in small tumours only (HR 9.26, p=0.04). Multivariate Cox 
regression analysis including HPV status, tumour localisation, 
stage, smoking status, tumour volume and hypoxia or the 
respective CSC marker showed a significant effect of the 
tumour volume (HR: 1.6-1.8, p<0.01), SLC3A2 (HR 2.03, 
p=0.02) or CD44 (HR 2.52, p=0.04) on LRC. Tumour hypoxia 
also reached borderline significance in small tumours (HR 
7.86, p=0.06). Interestingly, the tumour volume was an 
independent variable in all Cox models, a high tumour 
volume was significantly associated with poor LRC. Tumour 
volume and CSC marker expression also showed a negative 
prognostic impact on the secondary endpoints DM and OS.  
 
Conclusion: We have shown that large tumour volume and 
high CSC marker expression correlate with poor LRC in 
patients with locally advanced HNSCC who received primary 
RCT. In small tumours, hypoxia also had a negative impact. 
After validation of these promising results in the ongoing 
prospective study of our study group, these biomarkers may 
help to further stratify patients for individualised treatment 
escalation or de-escalation strategies. 
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